TransMedics Group logo
TransMedics Group TMDX
$ 99.75 -2.4%

Annual report 2025
added 02-24-2026

report update icon

TransMedics Group Income Statement 2011-2026 | TMDX

Annual Income Statement TransMedics Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.69 B 2.45 B 2.89 B 2.22 B 438 M 563 M 281 M - - - - - - - -

Shares

34 M 33.2 M 32.5 M 29.6 M 27.6 M 24.7 M 14.2 M - - - - - - - -

Historical Prices

138 73.7 88.9 75.2 15.9 22.8 17.5 - - - - - - - -

Net Income

190 M 35.5 M -25 M -36.2 M -44.2 M -28.7 M -33.5 M -23.8 M -20.8 M -24.1 M - - - - -

Revenue

605 M 442 M 242 M 93.5 M 30.3 M 25.6 M 23.6 M 13 M 7.68 M 6.21 M - - - - -

Cost of Revenue

243 M 179 M 87.5 M 28.2 M 9.1 M 9 M 9.74 M 7.28 M - - - - - - -

Gross Profit

363 M 262 M 154 M 65.3 M 21.2 M 16.6 M 13.9 M 5.73 M 2.14 M 766 K - - - - -

Operating Income

109 M 37.5 M -28.7 M -31.4 M -39.4 M -26.4 M -29.6 M -20.2 M - - - - - - -

Interest Expense

- - - - 3.87 M 3.98 M 4.35 M 2.72 M - - - - - - -

EBITDA

136 M 57.3 M -20.6 M -28 M -37.6 M -24.8 M -28.4 M -19.5 M -19.8 M -22.6 M - - - - -

Operating Expenses

254 M 225 M 183 M 96.7 M 60.6 M 43 M 43.5 M 26 M 22.6 M 23.8 M - - - - -

General and Administrative Expenses

185 M 169 M 120 M 69.9 M 38.3 M 24.2 M 23.6 M 12.3 M 7.61 M - - - - - -

All numbers in USD currency

Quarterly Income Statement TransMedics Group

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

33.9 M 33.7 M 33.6 M 33.4 M 33.1 M 32.8 M 32.7 M 32.6 M 32.5 M 32.3 M 32.1 M 30.2 M 28 M 28 M 27.8 M 27.7 M 27.6 M 27.4 M 27.2 M 27.2 M 23.3 M 21.2 M 21.2 M 21.1 M 13.1 M 1.42 M 1.4 M 1.37 M 4.69 M 1.36 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

34.9 M 25.7 M - 4.22 M 12.2 M 12.2 M - -25.4 M -1 M -2.64 M - -7.43 M -11.5 M -10.6 M - -13 M -10.7 M -7.92 M -6.31 M -5.09 M -8.5 M -8.85 M -9.18 M -8.28 M -9.2 M -6.9 M -7.64 M -5.1 M -6.12 M -4.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

157 M 144 M - 109 M 114 M 96.8 M - 66.4 M 52.5 M 41.6 M - 25.7 M 20.5 M 15.9 M - 5.37 M 8.17 M 7.05 M 7.63 M 7.09 M 3.39 M 7.53 M 6.06 M 7.2 M 5.67 M 4.68 M 3.54 M 4.04 M 2.92 M 2.52 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

60.8 M 55.3 M - 47.9 M 45 M 36.9 M - 25.8 M 15.7 M 12.8 M - 7.57 M 6.17 M 3.78 M - 1.6 M 2.58 M 2.24 M - 2.05 M 1.48 M 2.67 M - 2.99 M 2.33 M 2.1 M - 1.91 M 1.74 M 1.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

96.6 M 88.2 M - 60.8 M 69.3 M 60 M - 40.7 M 36.7 M 28.8 M - 18.1 M 14.4 M 12.1 M - 3.77 M 5.59 M 4.81 M 4.83 M 5.04 M 1.91 M 4.86 M 3.74 M 4.22 M 3.33 M 2.57 M 1.5 M 2.13 M 1.18 M 924 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

36.6 M 27.4 M - 3.92 M 12.5 M 12.4 M - -28.3 M -906 K -2.09 M - -5.54 M -9.74 M -9.37 M - -11.7 M -9.87 M -6.51 M -5.9 M -4.61 M -7.86 M -8.02 M -8.69 M -7.24 M -7.7 M -5.96 M -6.36 M -3.94 M -5.16 M -4.78 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - 3.62 M 3.6 M - 3.59 M 2.5 M 1.09 M - 787 K 972 K 960 K - 979 K 965 K 952 K - 971 K 1 M 1.04 M - 1.08 M 1.11 M 1.09 M - 1.08 M 313 K 258 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

36.7 M 33.6 M - 4.02 M 12.6 M 16.7 M - - - -802 K - -3.35 M -9.74 M -8.86 M - -10.4 M -9.87 M -6.06 M -5.9 M -3.46 M -7.12 M -7.65 M -8.69 M -6.38 M -7.17 M -5.72 M -6.36 M -3.39 M -4.82 M -4.62 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

60 M 60.8 M - 56.9 M 56.8 M 47.5 M - 69 M 37.6 M 30.9 M - 23.7 M 24.1 M 21.5 M - 15.5 M 15.5 M 11.3 M - 9.65 M 9.77 M 12.9 M - 11.5 M 11 M 8.54 M - 6.07 M 6.34 M 5.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

44.1 M 43.6 M - 42.7 M 42.9 M 36.2 M - 30.7 M 29.4 M 25 M - 16.9 M 17.4 M 13.9 M - 10.3 M 9.16 M 6.79 M - 5.49 M 5.87 M 6.65 M - 6.52 M 6.25 M 4.65 M - 2.8 M 2.9 M 2.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company TransMedics Group (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Sintx Technologies Sintx Technologies
SINT
$ 2.3 -4.96 % $ 6.38 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Align Technology Align Technology
ALGN
$ 166.05 -6.36 % $ 12.4 B usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 3.79 -5.61 % $ 61.9 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 328.87 -1.15 % $ 126 B usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.97 -4.78 % $ 1.65 B usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 26.49 -1.08 % $ 606 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.67 -10.47 % $ 31.5 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.38 1.99 % $ 39.1 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 104.91 0.33 % $ 183 B usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 21.24 -8.92 % $ 1.44 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 69.46 -1.01 % $ 103 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 35.4 -3.38 % $ 1.1 B usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 56.7 -5.36 % $ 1.68 B costa-ricaCosta-rica
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 9.27 0.54 % $ 361 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.61 1.65 % $ 33.2 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.14 -5.73 % $ 3.34 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.82 0.32 % $ 448 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 79.47 -3.2 % $ 46.5 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Beyond Air Beyond Air
XAIR
$ 0.72 4.06 % $ 48.7 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.55 -2.12 % $ 73.5 M usaUSA
Inogen Inogen
INGN
$ 6.29 -3.31 % $ 167 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 88.46 -0.77 % $ 18 B usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.16 -2.19 % $ 1.51 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.81 -3.3 % $ 371 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Ra Medical Systems Ra Medical Systems
RMED
- 10.0 % $ 610 K usaUSA